Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: Final analysis of a phase I/II trial

被引：132

作者：

Kankaanranta, Leena ^{[1
]}

Seppälä, Tiina ^{[4
,5
]}

Koivunoro, Hanna ^{[4
,5
]}

Saarilahti, Kauko ^{[1
]}

Atula, Timo ^{[2
]}

Collan, Juhani ^{[1
]}

Salli, Eero ^{[3
]}

Kortesniemi, Mika ^{[3
]}

Uusi-Simola, Jouni ^{[3
,4
]}

Välimäki, Petteri ^{[4
,5
]}

Mäkitie, Antti ^{[2
]}

Seppänen, Marko ^{[6
]}

Minn, Heikki ^{[7
]}

Revitzer, Hannu ^{[8
]}

Kouri, Mauri ^{[1
]}

Kotiluoto, Petri ^{[9
]}

Seren, Tom ^{[9
]}

Auterinen, Iiro ^{[9
]}

Savolainen, Sauli ^{[3
,4
]}

Joensuu, Heikki ^{[1
]}

机构：

[1] Department of Oncology, Helsinki University Central Hospital, FIN-00029 Helsinki

[2] Department of Otorhinolaryngology, Helsinki University Central Hospital, Helsinki

[3] Helsinki and Uusimaa Hospital District Medical Imaging Center, Helsinki University Central Hospital, Helsinki

[4] Department of Physics, University of Helsinki, Helsinki

[5] Boneca Corporation, Helsinki

[6] Turku PET Centre, Turku University Hospital, Turku

[7] Department of Oncology, Turku University Central Hospital, Turku

[8] Aalto University School of Science and Technology, Esopo

[9] VTT Technical Research Centre of Finland, Espoo

来源：

International Journal of Radiation Oncology Biology Physics | 2012年 / 82卷 / 01期

基金：

芬兰科学院;

关键词：

Boron neutron capture therapy; Boronophenylalanine; Head-and-neck cancer; Radiotherapy;

D O I：

10.1016/j.ijrobp.2010.09.057

中图分类号：

学科分类号：

摘要：

Purpose: To investigate the efficacy and safety of boron neutron capture therapy (BNCT) in the treatment of inoperable head-and-neck cancers that recur locally after conventional photon radiation therapy. Methods and Materials: In this prospective, single-center Phase I/II study, 30 patients with inoperable, locally recurred head-and-neck cancer (29 carcinomas and 1 sarcoma) were treated with BNCT. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 50 to 98 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed by use of the RECIST (Response Evaluation Criteria in Solid Tumors) and adverse effects by use of the National Cancer Institute common terminology criteria version 3.0. Intravenously administered L-boronophenylalanine-fructose (400 mg/kg) was administered as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Twenty-six patients received BNCT twice; four were treated once. Of the 29 evaluable patients, 22 (76%) responded to BNCT, 6 (21%) had tumor growth stabilization for 5.1 and 20.3 months, and 1 (3%) progressed. The median progression-free survival time was 7.5 months (95% confidence interval, 5.4-9.6 months). Two-year progression-free survival and overall survival were 20% and 30%, respectively, and 27% of the patients survived for 2 years without locoregional recurrence. The most common acute Grade 3 adverse effects were mucositis (54% of patients), oral pain (54%), and fatigue (32%). Three patients were diagnosed with osteoradionecrosis (each Grade 3) and one patient with soft-tissue necrosis (Grade 4). Late Grade 3 xerostomia was present in 3 of the 15 evaluable patients (20%). Conclusions: Most patients who have inoperable, locally advanced head-and-neck carcinoma that has recurred at a previously irradiated site respond to boronophenylalanine-mediated BNCT, but cancer recurrence after BNCT remains frequent. Toxicity was acceptable. Further research on novel modifications of the method is warranted. Copyright © 2012 Elsevier Inc. Printed in the USA. All rights reserved.

引用

页码：e67 / e75

页数：8

共 32 条

[1]

Wong L.Y., Wei W.I., Lam L.K., Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery, Head Neck, 25, pp. 953-959, (2003)

[2]

Gilbert H., Kagan A.R., Recurrence patterns in squamous cell carcinoma of the oral cavity, pharynx, and larynx, J Surg Oncol, 6, pp. 357-380, (1974)

[3]

Tan H.K., Giger R., Auperin A., Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas - Stratification for postsalvage survival, Head Neck, 32, pp. 139-147, (2010)

[4]

Tanvetyanon T., Padhya T., McCaffrey J., Prognostic factors for survival after salvage reirradiation of head and neck cancer, J Clin Oncol, 27, pp. 1983-1991, (2009)

[5]

Spencer S.A., Harris J., Wheeler R.H., RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck, Int J Radiat Oncol Biol Phys, 51, pp. 1299-1304, (2001)

[6]

Janot F., De Raucourt D., Benhamou E., Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma, J Clin Oncol, 26, pp. 5518-5523, (2008)

[7]

Salama J.K., Vokes E.E., Chmura S.J., Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma, Int J Radiat Oncol Biol Phys, 64, pp. 382-391, (2006)

[8]

De Crevoisier R., Bourhis J., Domenge C., Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients, J Clin Oncol, 16, pp. 3556-3562, (1998)

[9]

Barth R.F., Coderre J.A., Vicente G.H., Boron neutron capture therapy of cancer: Current status and future prospects, Clin Cancer Res, 11, pp. 3987-4002, (2005)

[10]

Wittig A., Collette L., Appelman K., EORTC trial 11001: Distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial, J Cell Mol Med, 13, pp. 1653-1665, (2009)

← 1 2 3 4 →